These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9504543)

  • 1. Rational therapy of Guillain-Barré syndrome.
    Samman I; Wöhrle JC; Hennerici M
    Lancet; 1998 Mar; 351(9104):753-4. PubMed ID: 9504543
    [No Abstract]   [Full Text] [Related]  

  • 2. Rational therapy of Guillain-Barré syndrome.
    Berciano J
    Lancet; 1998 Mar; 351(9104):754-5. PubMed ID: 9504544
    [No Abstract]   [Full Text] [Related]  

  • 3. Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases.
    Stangel M; Toyka KV; Gold R
    Arch Neurol; 1999 Jun; 56(6):661-3. PubMed ID: 10369303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulating the immune response in demyelinating diseases.
    Hughes R
    J Neurol Neurosurg Psychiatry; 1998 Feb; 64(2):148. PubMed ID: 9489519
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term treatment of chronic relapsing inflammatory demyelinating polyradiculoneuropathy: combination of corticosteroids, plasma exchange, and intravenous immunoglobulins.
    Briellmann RS; Nydegger UE; Sturzenegger M; Fierz L; Hess CW; Hauser SP
    Eur Neurol; 1998; 39(3):190-1. PubMed ID: 9605400
    [No Abstract]   [Full Text] [Related]  

  • 6. Future developments in the treatment of immune-mediated polyneuropathies.
    van der Meché FG; van Doorn PA
    Eur Neurol; 1997; 38(3):230-7. PubMed ID: 9363836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic demyelinating polyneuropathy in pregnancy treated with intravenous immunoglobulin.
    Nwosu EC; Tandon S; Breeze C; Enevoldson TP; Khaleeli AA
    Br J Obstet Gynaecol; 1999 Feb; 106(2):174-6. PubMed ID: 10426685
    [No Abstract]   [Full Text] [Related]  

  • 8. Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome.
    Gürses N; Uysal S; Cetinkaya F; Işlek I; Kalayci AG
    Scand J Infect Dis; 1995; 27(3):241-3. PubMed ID: 8539548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-D immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy.
    Vermeulen M; van Schaik IN; Brand A
    J Neurol Neurosurg Psychiatry; 1995 Mar; 58(3):383-4. PubMed ID: 7897433
    [No Abstract]   [Full Text] [Related]  

  • 10. Rational therapy of Guillain-Barré syndrome.
    Raphael JC; Chevret S
    Lancet; 1998 Mar; 351(9104):753. PubMed ID: 9504542
    [No Abstract]   [Full Text] [Related]  

  • 11. [Intravenous immunoglobulins in Guillain-Barré syndrome].
    Hidou M; Olivier J; Vivant JF
    Ann Fr Anesth Reanim; 1992; 11(1):115. PubMed ID: 1443803
    [No Abstract]   [Full Text] [Related]  

  • 12. Intravenous immunoglobulin in two children with Guillain-Barré syndrome.
    Notarangelo LD; Duse M; Tiberti S; Guarneri B; Brunori A; Negrini A; Ugazio AG
    Eur J Pediatr; 1993 Apr; 152(4):372-4. PubMed ID: 8482293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Value of intravenous immunoglobulins. A case of Guillain-Barré syndrome].
    Hidou M; Olivier J; Vivant JF
    Rev Neurol (Paris); 1992; 148(11):706-8. PubMed ID: 1303562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guillain-Barré syndrome: the evolution of therapy.
    Cornblath DR; Hughes RA
    J Neurol; 1994 May; 241(6):404-5. PubMed ID: 7931438
    [No Abstract]   [Full Text] [Related]  

  • 15. Single-dose intravenous immune globulin for treatment of Guillain-Barré syndrome.
    McGhee B; Jarjour IT
    Am J Hosp Pharm; 1994 Jan; 51(1):97-9. PubMed ID: 8135270
    [No Abstract]   [Full Text] [Related]  

  • 16. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.
    Thompson N; Choudhary P; Hughes RA; Quinlivan RM
    J Neurol; 1996 Mar; 243(3):280-5. PubMed ID: 8936360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of intravenous immunoglobulins in Guillain-Barré syndrome].
    Ceccarelli M; Assanta N; Chiaravalloti G; Rocopou C; Caiulo VA
    Minerva Pediatr; 1992 May; 44(5):237-40. PubMed ID: 1620076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent aseptic meningitis complicating intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy.
    Vera-Ramirez M; Charlet M; Parry GJ
    Neurology; 1992 Aug; 42(8):1636-7. PubMed ID: 1641167
    [No Abstract]   [Full Text] [Related]  

  • 19. The Guillain-Barré syndrome: plasma exchange or immunoglobulins intravenously.
    van der Meché FG
    J Neurol Neurosurg Psychiatry; 1994 Nov; 57 Suppl(Suppl):33-4. PubMed ID: 7964849
    [No Abstract]   [Full Text] [Related]  

  • 20. Intravenous immunoglobulins versus plasmapheresis in older patients with Guillain-Barre syndrome.
    Rana SS; Rana S
    J Am Geriatr Soc; 1999 Nov; 47(11):1387-8. PubMed ID: 10573458
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.